Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS-FGFR4RX in Obese Patients
NCT02476019Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Jul 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of IONIS-FGFR4Rx in obesity, sponsored by Ionis Pharmaceuticals. Started Jun 2015; status: completed.
02
Drugs
IONIS-FGFR4Rx
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02476019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02476019.